

CYTYC CORP  
Form 425  
June 14, 2007

Needham & Company  
Sixth Annual Biotechnology &  
Medical Technology Conference  
Jack W. Cumming  
Chairman & CEO

Glenn Muir  
Executive VP & CFO  
June 14, 2007  
Filed by Hologic, Inc.  
Pursuant to Rule 425 under the  
Securities Act of 1933 and deemed  
filed pursuant to Rule 14a-12 of  
the Securities Exchange Act of 1934  
Subject Company: Cytoc  
Corporation  
Commission File No.: 000-27558

Disclaimer Regarding Forward-Looking  
Statements

Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to,

statements  
about  
the  
anticipated  
benefits  
of  
Hologic's  
products,  
the  
timing

of the completion of the transaction between Hologic and Cytoc, the anticipated benefits of the business combination transaction involving Hologic and Cytoc, including future financial and operating results, the expected permanent financing for the transaction, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Hologic and Cytoc caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information.

These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties may be unable to complete the transaction because conditions to the closing of the transaction may not be satisfied; the risk that the businesses will not be integrated successfully; the transaction may involve unexpected costs or unexpected liabilities; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal

Disclaimer Regarding Forward-Looking  
Statements (continued)

growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-party reimbursement; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange

rate  
fluctuations  
on  
international  
operations.

In  
addition,  
the  
transaction  
will  
require  
the  
combined company  
to  
obtain  
significant  
financing.

While  
Hologic  
has  
obtained

a  
commitment to obtain such financing, including a bridge to the permanent financing  
contemplated in the presentation, the combined company's liquidity and results of operations  
could be materially adversely affected if such financing is not available on favorable terms.

Moreover, the  
substantial  
leverage  
resulting  
from  
such  
financing  
will  
subject  
the  
combined

company's business to additional risks and uncertainties. The risks included above are not  
exhaustive. The annual reports on Form 10-K, the quarterly reports on Form 10-Q, current  
reports on

Form  
8-K  
and  
other  
documents  
Hologic  
and  
Cytoc  
have  
filed  
with

the  
SEC  
contain additional factors that could impact the combined company's businesses and  
financial performance. The parties expressly disclaim any obligation or undertaking to  
release publicly  
any  
updates  
or  
revisions  
to  
any  
such  
statements  
to  
reflect  
any  
change  
in  
the  
parties  
expectations or any change in events, conditions or circumstances on which any such  
statement is based.

Important Information for Investors and  
Stockholders

Hologic and Cytoc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. **HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED BY EITHER PARTY WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT**



INFORMATION.

Investors and stockholders will be able to obtain the joint proxy statement/prospectus and other documents

filed

with

the

SEC

free

of

charge

at

the

website

maintained

by

the

SEC

at

[www.sec.gov](http://www.sec.gov). In addition, documents filed with the SEC by Hologic will be available free of charge on the investor relations portion of the Hologic website at [www.hologic.com](http://www.hologic.com).

Documents filed with the SEC by Cytac will be available free of charge on the investor relations portion of the Cytac website at [www.cytac.com](http://www.cytac.com).

Participants in the Solicitation

Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic's directors and executive officers and a description of their interests in Hologic are set forth in the proxy statement for Hologic's 2006 annual meeting of stockholders, which was

filed  
with  
the  
SEC  
on  
January  
25,  
2007.

Cytec,  
and  
certain

of  
its  
directors and executive officers, may be deemed to be participants in the solicitation of  
proxies from  
its  
stockholders

in  
connection  
with  
the  
merger.

The  
names  
of  
Cytec's  
directors

and executive officers and a description of their interests in Cytec is set forth in Cytec's  
Annual Report on Form 10-K/A for the fiscal year ended December 31, 2006, which was  
filed with the SEC on April 30, 2007. Investors and stockholders can obtain more detailed  
information regarding the direct and indirect interests of Hologic's and Cytec's directors and  
executive officers

in  
the  
merger  
by  
reading  
the  
definitive  
joint  
proxy  
statement/prospectus  
when it becomes available.

Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and EBITDA . Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets,  
and  
tax

provisions/benefits  
related  
thereto.

EBITDA

is  
defined

as

net

earnings (loss) before interest, taxes, depreciation and amortization expense. Neither  
adjusted EPS nor EBITDA is a measure of operating performance under GAAP. We believe  
that the use of these non-GAAP measures helps investors to gain a better understanding of

our core

operating

results

and

future

prospects,

consistent

with

how

management

measures

and forecasts our performance, especially when comparing such results to previous periods  
or forecasts. When analyzing our operating performance, investors should not consider these  
non-GAAP measures as a substitute for net income prepared in accordance with GAAP.

A History of Innovation  
Delphi  
HOLOGIC  
Goes Public  
Acquisition of  
Trex  
Medical

Including LORAD  
Selenia  
Launched  
in U.S.  
Introduced  
3D DEXA  
Acquisition  
of R2, Suros  
and AEG  
Fan-Beam  
Technology  
Founding of  
HOLOGIC  
Announced  
Agreement  
with  
Cytoc  
Introduced  
Tomosynthesis at  
RSNA  
Launched  
Discovery  
Acquisition  
of Direct  
Radiography  
1986  
1990  
1995  
1998  
1999  
2000  
2002  
2003  
2004  
2005  
2007  
\$463M  
\$288M  
\$720E  
2006

Women's health imaging market leader

Strong/profitable core businesses (breast health/densitometry)

Technology and market share leader (# 1 market share in U.S.)

Major opportunity -  
digital mammography/interventional market



Large, emerging digital and interventional markets

Digital technology emerging as the standard of care

Less invasive procedures for biopsy and therapy gaining ground

>50% growth rate in FY-05 and FY-06

Expanded distribution (U.S. sales team doubled in FY-06)

Sound capital foundation

Hologic Overview

Hologic Overview

Financial Overview  
Record Q2 FY07  
revenues  
of \$180 million  
Record Q2 FY07 pre-tax  
income of \$33.9 million  
Backlog of \$216 million as of

quarter-end 3/31/07

Q2 FY07 Performance (**March 31st**)

up 79%

over Q2 FY06

up 94%

over Q2 FY06

up 41% **Of**

\$63 million

over **3/25/06**

Strong Growth

Up 99%  
Over 1  
st  
Half FY06  
78% of Revenues  
LORAD Mammography/Breast Care  
Recognized technology leader worldwide

Market share leader in the U.S. >50% share in analog/digital  
Unsurpassed image quality

High transmission cellular grid -  
patented  
Largest installed base

13,000 system

\$129

\$189

\$270

\$336

'04

'05

'06

1st Half '07

Fiscal Year

Mammography/Breast Care Revenue

\$ in Millions

Up 77%

Over FY05

Direct Conversion  
Technology Optimal  
> 72% of Mammography/Breast Care Product Revenue  
LORAD Selenia FFDM  
First U.S. system delivered  
in March 2003  
555 Selenias

sold in FY06  
228 Selenias  
sold in Q1 FY07  
282 Selenias  
sold in Q2 FY07  
Backlog  
increased to 533  
systems at end  
of Q2 FY07  
up 132%  
over FY05  
up 135%  
over Q1 FY06  
up 248  
systems  
over Q2 FY06  
up 154%  
over Q2 FY06

282  
37  
35  
228  
193  
154  
111



97  
71  
64  
54  
50  
44  
27  
27  
3  
11  
16  
Q1  
Q2  
Q3  
Q4  
Q1  
Q2  
Q3  
Q4  
Q1  
Q2  
Q3  
Q4  
Q1  
Q2  
Q3  
Q4  
Q1  
Q2  
Q2

Selenia Highlights:

555 sold in FY06

510 sold in first half of FY07

Approximately 38% of  
estimated 3,900+ worldwide

FFDM installed market

Accelerating

Interest

\*For

Fiscal

Years

Ended

September

30

th

Number of Selenia s Sold\*

Full Field Digital Mammography

2003

2004

2005

2006

2007

MQSA U.S. Scorecard\*  
(Mammography Quality Standards Act of 1992)  
Total Certified Facilities  
8,812  
Total Accredited Units  
13,446  
Certified Facilities with FFDM Units

1,884

21.4%

Accredited FFDM Units

2,773 **20.6%**

Total U.S. Annual

= 34.8 Million

Mammography Procedures

Hologic U.S. Installed Base approximately 45% of FFDM units

\*(<http://www.fda.gov/cdrh/mammography>)

Certified Statistics as of June 1, 2007

Normal  
Mammogram  
Tomosynthesis:  
3-D Visualization of Breast Tissue  
The Next Frontier for Digital Mammography  
Multiple views reconstructed into 3D image  
Helps solve tissue overlap problems

Lower recall rates -  
Improved detection  
Tomosynthesis Slices  
\* Works-in-progress



Vacuum Assist Breast  
Biopsy Systems  
Leading technology for VABB  
Leverages U.S. sales and  
distribution channels  
FY06 sales of approximately  
\$38 million



High gross margin product  
exceeding 65%

Over 70% of revenues derived  
from recurring disposable  
sales

Expected growth rate of over  
50% in each of next  
two years  
Worldwide market currently estimated  
at \$250 million

1.8m biopsies in U.S. -  
1/3 vacuum  
assisted

International market represents new  
opportunity

Celero

-

The First Vacuum-Assisted, Spring-Loaded Core Biopsy Device for Breast Ultrasound  
Celero breast biopsy device with CeleroMark biopsy marker system and introducer

Celero Advantages

- - Faster and less traumatic for the patient
  - 
  - Provides better access to hard-to-reach lesions
  - 
  - Better **cores** that are more than two times the size of conventional spring loaded core devices
  - 
  - More accurate clinical diagnosis
  - 
  - Better confirmation with the needle clearly visible under ultrasound imaging
- Celero Market
- - 600,000 Core Needle Biopsies per year
  - 
  - Surgery Call Point

Ultrasound  
Stereotactic  
MRI  
500,000 (ATEC Market)  
1.8 Million  
Breast Biopsy  
Procedures

Annually in the  
U.S.

600,000

(Celero Market)

700,000

Suros ATEC

®

and Celero

Systems

Ideally Positioned to Capture the Biopsy Market

Creating a Global Leader in  
Women's Healthcare  
Continuing a legacy of leading technology, innovation and rapid growth

Transaction Overview **(May 20, 2007)**

Permanent financing anticipated to be combination of pre-payable term loan and equity-linked securities

Financing:

Hologic, Inc. (NASDAQ: HOLX), continue Cytyc name

Name of NewCo:

Third Quarter of CY2007

Timing to Close:

Shareholders of both companies, customary closing conditions and anti-trust clearance, including HSR and various country filings

Customary Approvals:

Chief Executive Officer: Jack Cumming

Management:

Chairman of the Board: Patrick Sullivan

Hologic: 6 Directors

Cytyc: 5 Directors

Board Composition:

Hologic:

45%

Cytyc:

55%

Pro Forma Ownership:

0.520 Hologic shares and \$16.50 for each Cytyc share valued at \$46.46 per share or 33% premium, for approximate total consideration of \$2.2B in cash and \$4.0B in stock

Purchase Consideration:



Expansive women's healthcare product portfolio

-

Nine number #1 brands in market

Significant cross-selling synergies

-

Ability to leverage OB/GYN channel

-

Ability to leverage Surgical and Radiation Oncology channel for

Hologic's new products pipeline

Enhanced international presence

Over 200 sales and service associates in 20 international offices

R&D efforts in interventional and therapy segment will accelerate

Strategic Advantages

Combined Strengths

Comprehensive Sales Coverage in U.S.

425+ sales team

Comprehensive Service Coverage in U.S.

250+ service team

Proven management team with record of successfully  
integrating acquisitions

Significant cash flow generation

~\$450M projected EBITDA in 2008

Accretive to adjusted EPS

1

within the first full year after close

1

Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and related tax effect.

Selenia  
Breast Cancer  
Screening  
MammoSite  
Radiation  
Therapy  
ThinPrep Pap Test & Imaging System

Cervical Cancer Screening

NovaSure

Endometrial

Ablation

Adiana

Contraception

FullTerm -

Adeza

Preterm Labor

Best-in-Class Solutions

for

Women s Healthcare

Comprehensive Women s Healthcare Platform

Discovery

Osteoporosis

Screening

MultiCare

Stereotactic

Biopsy

Suros

Biopsy Systems

Solutions for Major Women's Healthcare Issues

Helica

Adiana

Fetal Fibronectin

Discovery

Sahara

NovaSure

ThinPrep  
Selenia  
MultiCare  
Suros ATEC  
MammoSite  
Combined  
Offering  
Unpenetrated  
High  
Medium  
Low  
High  
Medium  
High  
Market Growth  
\$100M  
\$1B+  
\$400M  
\$110M  
\$2.5B+  
\$550M  
\$1B  
U.S. Market Size  
Endometriosis  
Permanent  
Contraception  
Preterm  
Labor  
Osteoporosis  
Menorrhagia  
Cervical  
Cancer  
Breast  
Cancer  
1 in 3  
1 in 4  
1 in 2  
Pregnancies  
1 in 2  
1 in 5  
1 in 138  
1 in 8  
U.S. Women  
Affected  
NM  
NM  
#1  
#1  
#1  
#1

#1

U.S. Market

Position

Gestiva

International

ThinPrep

Imager

International

Tomosynthesis

Suros Celero

Additional

Opportunities

International

International

International

International

International

\$0

\$0

\$60M

\$80M

\$230M

\$425M

\$600M

2007E Worldwide

Revenue

Source: Market research and company estimates.





OB/Gyn  
Screening  
Test  
Diagnostic  
Test  
Treatment  
Specialist  
Therapeutic  
Improved  
Outcomes  
Our Mission  
Leveraging the OB/GYN Channel  
Best Technology  
Selenia, ThinPrep,  
Adeza, Discovery  
Minimally Invasive

Most Specific

Suros, MultiCare,

Selenia, Discovery

Channel Access to

Gatekeeper

230 **OB/Gyn sales reps**

Channel Access to

Treatment Decision

maker

288 Breast surgeon, oncologist,

OB/Gyn sales reps

Targeted

Minimally Invasive

NovaSure,

MammoSite,

Gestiva, Adiana





Over 440 U.S. Sales Representatives  
Multiple call points to women's healthcare  
providers  
Access to

30,000 OB/Gyn's

40,000 Radiologists

10,000 Hospitals & Imaging centers

4,000 Radiation Oncologists

4,000 Gyn Surgeons

2,500 Breast Surgeons

5,000 Neurosurgeons

80,000 Primary Care Physicians

23,000 Orthopedists

4,000 Rheumatologists

Best-in-class brand recognition

In-Depth Channel Coverage

46 Breast Surgery

77

Radiology & Imaging Center

5

Ortho/Rheumo

45 Clinical Lab

8

Neurosurgery

110 Gynecology Surgery

12

Radiation Oncology

143

OB/Gyn & Primary Care







Product Pipeline

-

Current/Near and Mid/Long Term Revenue Potential

\$60

50

40

30

0

Current Products/New Markets

New Products/New Markets

Immediate

3 Years

+ 4 Years

Availability Timeline

Core Biopsy to Surgery

FFDM to Gynecology

MI Fibroid Adenoma Extraction to Surgery

Radiation Therapy to Rad Onc

MI Cancer Extraction to Surgery

Hologic proprietary

development of new products

for Cytoc Sales Channel

Tomosynthesis

Diversified and Balanced Revenue Mix

Gynecology

Interventional

16%

Gynecology

Diagnostics

33%

Breast Health

40%

Osteoporosis

& Other

11%

Combined Company

LQA Revenue

= \$1.44B

~ 40% Capital Equipment

~ 60% Consumables

Other

1%

MammoSite

5%

Adeza

8%

NovaSure

30%

Pap

56%

Other

12%

Breast Biopsy

9%

Osteoporosis

11%

Digital

Mammography

68%

Hologic

LQA Revenue = \$724M

Cytec

LQA Revenue

= \$720M

Multiple platforms to enhance top and bottom line growth  
Increased scale through diversification of revenue and  
strong margin profile  
Enhanced cash flow; LQA EBITDA of ~\$436M  
Revenue and cost synergy opportunities  
Estimated more  
than

\$0.10

accretive

to

adjusted

EPS

1

within

the first full year after close, significantly more accretive

thereafter

Rapid debt repayment, incremental earnings growth

Financial Rationale

1

Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and related tax effect.

Combined Financial Strength

46%

Gross Margin

\$161M

EBITDA

\$724M

Revenue

LQA  
Hologic  
75%  
Gross Margin  
\$275M  
EBITDA  
\$720M  
Revenue  
LQA  
Cytoc  
60%  
Gross Margin  
\$436M  
EBITDA  
\$1.44B  
Revenue  
LQA  
Combined Company  
Estimated more  
than  
\$0.10  
accretive  
to  
adjusted  
EPS  
1  
within  
the  
first  
full  
year  
after  
close -  
significantly more  
accretive  
thereafter  
(  
Adjusted  
EPS  
excludes  
the  
write-off  
and  
amortization  
of  
acquisition-related intangible assets, and related tax effect.)



\$25-\$30M projected cost savings within two years

Align assets to maximize efficiencies

Leverage combined purchasing power

Consolidate administrative activities

Greater than \$75M revenue projected opportunities within three years

Cross-selling to OB/Gyn/breast surgeon/mammographer/radiation oncologist

Enhanced geographic

reach

200

people

with

20

offices

Penetration of new and existing markets

\$10M in Cost Synergies Anticipated in Year One

Significant Synergy Opportunity

FY2008 Guidance and Long Term Outlook

2008 Guidance

Revenue: In excess of \$1.70B

Adjusted EPS

1

: \$2.35-\$2.40 / share

Gross margin: 65%

Long-Term Outlook

Revenue Growth: 20%

Adjusted EPS

1

Growth: 20%+

1

Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and related tax effect.

Creating a Global Leader in Women's Healthcare  
Comprehensive Women's Healthcare Product Portfolio

Complementary best-in-class technologies  
Expanded Commercial Capabilities

Expansive U.S. sales channel coverage

Enhanced presence in key international markets

Platform for entry into new markets

Opportunity to offer Integrated Solutions

Screening

Diagnostics

Therapeutics

Creating  
A Global Leader  
In Women's Healthcare